helping empower recovery the online series (heros) · helping empower recovery the online series...
Post on 11-Oct-2020
5 Views
Preview:
TRANSCRIPT
©2020 Baxter Healthcare Corporation
1
Helping Empower Recovery
The Online Series (Heros)
Part 3:
Early Nutritional Supplementation in
Non-ICU Hospitalized Covid-19 Patients
April 23, 2020
GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation 1
• Support for this program is provided by Baxter International Inc.
• This program is not an accredited continuing education (CE) program
• Today’s presentation slides and on-demand viewing of this program will be available by 30-April at:
– https://www.baxterglobal.com/nutrition_hero_series
Program Disclosure
2GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
1
2
©2020 Baxter Healthcare Corporation
2
Faculty
Alessandro Laviano, MD
Associate Professor of Internal Medicine
Department of Translational and Precision Medicine
Sapienza University
Rome, Italy
Riccardo Caccialanza, MD
Director of UOC Dietetics and Clinical Nutrition
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy
3GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
Disclosures
*honoraria for advisory boards, activities as a speaker,
travel grants, research grants
Potential conflicts of interest*:
Akern Fresenius Kabi
Angelini Ipsen
Baxter Mylan
B. Braun Nestlé Health Science
Boehringer Ingelheim Nutricia
Eli Lilly
Alessandro Laviano, MD
Riccardo Caccialanza, MD
4
Potential conflicts of interest:
Abbott Nestlé Health Science
Baxter Nutricia
B. Braun Smartfish
Fresenius Kabi
GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
3
4
©2020 Baxter Healthcare Corporation
3
• Address the nutritional requirements of COVID-19 patients
• Discuss the role of delivery and monitoring of nutrition support in the COVID-19 ICU patient
• Review of best practices experienced in treating COVID-19 patients
Objectives
5GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
Dipartimento di Medicina
Traslazionale e di Precisione
alessandro.laviano@uniroma1.it
Nutrition in the Time of COVID-19Alessandro Laviano
6GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
5
6
©2020 Baxter Healthcare Corporation
4
CORONAVIRUS DISEASE 2019
7GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
Rabi FA, et al. Pathogens 2020;9(3):231.
8GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
7
8
©2020 Baxter Healthcare Corporation
5
Zheng J. Int J Biol Sci. 2020;16(10):1678-1685.
Key Events in the Early Stage of SARS-CoV-2 Outbreak
9GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
Data exist to support the notion that SARS-CoVand MERS-CoV are viable in environmental conditions that could facilitate faecal-oral transmission. SARS-CoV RNA was found in the sewage water of two hospitals in Beijing treating patients with SARS1. When SARS-CoV was seeded into sewage water obtained from the hospitals in a separate experiment, the virus was found to remain infectious for 14 days at 4°C, but for only 2 days at 20°C1.
Charleen Yeo, Sanghvi Kaushal, *Danson Yeodanson_xw_yeo@ttsh.com.sg
Enteric Involvement of Coronaviruses: Is Faecal-Oral Transmission of SARS-CoV-2 Possible?
1. Initial genome release of novel coronavirus. http://virological.org/t/initial-genome-release-of-novel-coronavirus/319?from=groupmessage. (Accessed on 18 Feb 2020).
www.thelancet.xom/gastrohep. Vol 5, April 2020
10GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
9
10
©2020 Baxter Healthcare Corporation
6
Gibney E. Nature. 2020;580:176-177.
Coronavirus Lockdowns Have Changed the Way Earth Moves
SEISMIC NOISEIn Belgium, vibrations caused by human activity have fallen by about one-third since coronavirus containment measures were introduced.
11GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
Confirmed Cases and Deaths by Country, Territory, or Conveyance (as of 22 April 2020)
https://www.worldometers.info/coronavirus/?#countries
12GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
11
12
©2020 Baxter Healthcare Corporation
7
CORONAVIRUS DISEASE 2019
Unmet Needs and Unanswered Questions
13GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
The Mystery of the Mayan
Calendar.
WAS IT
2012OR IS IT
2020?
©Dave Granlund. www.davegranlund.com
14GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
13
14
©2020 Baxter Healthcare Corporation
8
1. Covinsky K, Katz M. Supplemental nutrition assistance program – Do not take the food out of patients’ mouth. JAMA Intern Med 2020. https://doi.org/10.1001/jamainternmed. 2019.7151. [Epub ahead of print, Accessed March 9,2020].
Nutrition support in the time of SARS-CoV-2 (COVID-19)
Nutrition is a key determinant of health1. More importantly, nutrition is part of the treatment regimen for acute and chronic diseases and applies particularly to ailments for which an etiologic treatment has not yet been discovered and validated.
2020
Laviano A, Koverech A, Zanetti M.
15GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
NEWS 10 April 2020Amy Maxmen
For Ebola in the Democratic
Republic of the Congo,
the end will have to wait
Just days before announcing the
official end of a devastating
outbreak, a new case emerges.
16GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
15
16
©2020 Baxter Healthcare Corporation
9
Saving Lives Without New Drugs
Callahan is helping an international team develop guidelines dubbed Maximum Use
of Supportive Therapy (MUST), aimed at keeping more patients alive. It includes intravenous
(IV) drips to replace massive fluid loss from diarrhea and vomiting, a risk factor for shock;
balancing of electrolytes such as calcium or potassium, which prevents kidney and heart
failure; nasogastric tubes for feeding; and testing and treatment of secondary infections such
as malaria. Introducing MUST will also make it easier to study new treatments, Callahan says:
Randomized controlled trials—ethically fraught because only some patients get the novel
treatment (see main story, p. 908)—will be much more acceptable if everyone receives
high-level care. In addition, MUST might reveal side effects of new drugs that would otherwise
be masked by Ebola symptoms, and it could reduce the rate of complications that might be
incorrectly blamed on a drug.
2014;346(6212):91. DOI: 10.1126/science.346.6212.911Jon Cohen
17GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
Bah EI, et al. N Engl J Med 2015; 372:40-47.
Clinical Presentation of Patients with Ebola Virus Disease in Conakry, Guinea
The case fatality rate that we observed in this cohort in the capital city of Conakry was lower than the rate reported in most studies of previous
EVD outbreaks (although not in all studies) and was lower than the rate in most other regions in Guinea at that point in the epidemic. Clinical
care at the main isolation facility near Donka Hospital was jointly provided by the Ministry of Heath, Médecins sans Frontières, and the WHO
during the study period. Adherence to new guidelines promoting increased medical interventions, particularly related to the use of oral and
intravenous fluids and electrolyte replacement, appropriate antibiotics, and targeted clinical laboratory testing, may have contributed to the
reduced case fatality rate, as compared with past outbreaks.
Figure 1. Kaplan–Meier Estimate of the Probability of Survival among Patients with Ebola Virus Disease, According to Age
Table 2. Therapies Received by 37 Patients Hospitalized for EVD
18GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
17
18
©2020 Baxter Healthcare Corporation
10
Obesity (Silver Spring) 2020 (epub ahead of print)
BRIEF CUTTING EDGE REPORTS
High prevalence of obesity in severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) requiring invasive mechanical ventilationSimonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, Labreuche J, Mathieu D, Pattou F, Jourdain M
First published: 09 April 2020 https://doi.org/10.1002/oby.22831
All PatientsN=124
InvasiveMechanical
Ventilation N=85
No InvasiveMechanical
Ventilation N=39
Male 90 (73) 64 (75) 26 (67)
Age (years) 60 (51-70) 60 (51-69) 60 (50-72)
Height (cm) 172 (166-178) 172 (166-178) 172 (165-180)
Weight (kg) 88 (80-108) 95 (81-112) 81 (75-94)
Body Mass Index (kg/m2) 29.6 (26.4-36.4) 31.1 (27.3-37.5) 27 (25.3-30.8)
Diabetes 28 (23) 23 (27) 5 (13)
Hypertension 60 (49) 48 (56) 12 (32)
Dyslipidemia 34 (28) 24 (28) 10 (26)
Table 1: Baseline characteristics of 124 patients admitted in intensive care for SARS-CoV-2, who required invasive mechanical ventilation (n=85) and those who did not (n=39).Results are expressed as median (IQR) for continuous variables and as frequency (percentage) for categorical variables.
19GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
*The denominators of patients who were included in the analysis are provided if they differed from the overall numbers in the group. Percentages may not total 100 because of rounding.†The primary composite end point was admission to an intensive care unit, the use of mechanical ventilation, or death.¶The presence of hepatitis B infection was defined as a positive result on testing for hepatitis B surface antigen with or without elevated levels of alanine or aspartate aminotransferase.||Included in this category is any type of cancer.
W Guan, et al. N Engl J Med. 2020. DOI: 10.1056/NEJMoa2002032.
Clinical Characteristics of Coronavirus Disease 2019 in China
Table 1. Clinical Characteristics of the Study Patients, According to Disease Severity and the Presence or Absence of the Primary Composite End Point.
20GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
19
20
©2020 Baxter Healthcare Corporation
11
Zhou F, et al. Lancet 2020;395:1054-1062.
Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study
Demographics and Clinical Characteristics
Total
(n=191)
Non-survivor
(n=54)
Survivor
(n=137) P Value
Age, Years56·0
(46·0–67·0)
69·0
(63·0–76·0)
52·0
(45·0–58·0)<0·0001
Sex — — — 0·15
Female 72 (38%) 16 (30%) 56 (41%) —
Male 119 (62%) 38 (70%) 81 (59%) —
Exposure History 73 (38%) 14 (26%) 59 (43%) 0·028
Current Smoker 11 (6%) 5 (9%) 6 (4%) 0·21
Comorbidity 91 (48%) 36 (67%) 55 (40%) 0·0010
Hypertension 58 (30%) 26 (48%) 32 (23%) 0·0008
Diabetes 36 (19%) 17 (31%) 19 (14%) 0·0051
Coronary Heart
Disease15 (8%) 13 (24%) 2 (1%) <0·0001
Chronic Obstructive
Lung Disease6 (3%) 4 (7%) 2 (1%) 0·047
Carcinoma 2 (1%) 0 2 (1%) 0·37
Chronic Kidney
Disease2 (1%) 2 (4%) 0 0·024
Other 22 (12%) 11 (20%) 11 (8%) 0·016
Laboratory Findings
Total
(n=191)
Non-survivor
(n=54)
Survivor
(n=137) P Value
White Blood Cell
Count, × 10⁹ per L
6·2
(4·5–9·5)
9·8
(6·9–13·9)
5·2
(4·3–7·7)<0·0001
<4 32 (17%) 5 (9%) 27 (20%) <0·0001*
4–10 119 (62%) 24 (44%) 95 (69%) —
>10 40 (21%) 25 (46%) 15 (11%) —
Lymphocyte Count,
× 10⁹ per L
1·0
(0·6–1·3)
0·6
(0·5–0·8)
1·1
(0·8–1·5)<0·0001
<0·8 77 (40%) 41 (76%) 36 (26%) <0·0001
Haemoglobin, g/L128·0
(119·0–140·0)
126·0
(115·0–138·0)
128·0
(120·0–140·0)0·30
Albumin, g/L32·3
(29·1–35·8)
29·1
(26·5–31·3)
33·6
(30·6–36·4)<0·0001
ICU Admission 50 (26%) 39 (72%) 11 (8%) <0·0001
ICU Length of Stay,
Days8·0 (4·0–12·0) 8·0 (4·0–12·0) 7·0 (2·0–9·0) 0.41
21GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
Zhou F, et al. Lancet 2020;395:1054-1062.
Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study
22GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
21
22
©2020 Baxter Healthcare Corporation
12
Wu C, et al. JAMA Int Med. 2020 (epub ahead of print)
Initial prealbumin levels are lower in patients who developed ARDS vs
patients who did not.
Is this a sign of acute malnutrition
or increased inflammatory response?
Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
23GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
Table 3. Complications, Treatments, and Clinical Outcomes
Guan W, et al. N Engl J Med. 2020
24GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
23
24
©2020 Baxter Healthcare Corporation
13
Lin L, et al. Gut 2020 (epub head of print)
Gastrointestinal Symptoms of 95 Cases with SARS-CoV-2 Infection
25GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
Zheng J. Int J Biol Sci. 2020;16(10):1678-1685.
Gastrointestinal Symptoms of 95 Cases with SARS-CoV-2 Infection
Figure 1. Gastroscopy of the oesophagus in a severe patient with SARS-CoV-2 infection. A and B were different parts of the oesophagus under the endoscopy.
(A) A round ulcer (4–6 mm in size) was covered with white moss.
(B) Some ulcers were fused into pieces with a small amount of bleeding.
26GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
25
26
©2020 Baxter Healthcare Corporation
14
GI
Symptoms
(n=74)
GI
Symptoms
(n=577) P value
>38,5° C 39% 17% <0,001
Lymphocytes
(x109/L)0,97 1,2 0,001
CRP (mg/L) 15,6 7,9 0,003
Shortness
of Breath10,8% 3,3% 0,007
Fatigue 31% 16% 0,004
Headache 21% 8% 0,002
Jin X, et al. Gut 2020 (epub ahead of print)
Epidemiological, clinical and virological Characteristics of 74 Cases of Coronavirus-infected Disease 2019 (COVID-19) with Gastrointestinal Symptoms Table 1. Demographic and epidemiological characteristics
of patients with COVID-19 with and without GI symptoms
Data are presented as medians (IQR), n (%) and n/N (%). COPD=chronic obstructive pulmonary disease
27GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
2. General Treatment
2.1. Letting patients rest in bed and strengthening support therapy;
ensuring sufficient caloric intake for patients; monitoring their water
and electrolyte balance to maintain internal environment stability;
closely monitoring vital signs and oxygen saturation.
Diagnosis and Treatment Protocol for Novel Coronavirus PneumoniaTrial Version 7. Released by National Health Commission & State Administration of Traditional Chinese Medicine on March 3, 2020
28GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
27
28
©2020 Baxter Healthcare Corporation
15
Volume 5, ISSUE 5, P426-428, May 01, 2020
Mao R, Liang J, Shen J, Ghosh S, Zhu L, Yang H, Wu K, Chen M
Implications of COVID-19 for patients with pre-existing digestive diseases
Medication for Patients with IBD
• Continue current treatment if disease is stable, and contact your doctor for suitable medicine if disease has flared
• Use of mesalamine should be continued and should not increase the risk of infection
• Corticosteroid use can be continued, but be cautious of possible side-effects
• A new prescription of immunosuppressant or increase in dose of an ongoing immunosuppressant is not recommended in epidemic areas.
• Use of biologics such as the anti-TNFs infliximab or adalimumab should be continued
• If infliximab infusion is not accessible, switching to adalimumab injection at home is encouraged
• Vedolizumab use can be continued due to the specificity of the drug for the intestine
• Ustekinumab use can be continued, but starting ustekinumab requires infusion centre visits and therefore is not encouraged
• Enteral nutrition might be used if biologics are not accessible
• Tofacitinib should not be newly prescribed in epidemic areas unless there are no other alternatives
29GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
Journals Intensive Care Medicine (ICM) and Critical Care Medicine (CCM). DOI: 10.1007/s00134-020-06022-5
© European Society of Intensive Care Medicine and the Society of Critical Care Medicine 2020
Surviving Sepsis Campaign: Guidelines on the Management
of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19)
Alhazzani W, Hylander Møller M, Arabi YM, Loeb M, Ng Gong M, Fan E, Oczkowski S, Levy MM, Derde L, Dzierba A,
Du B, Aboodi M, Wunsch H, Cecconi M, Koh Y, Chertow DS, Maitland K, Alshamsi F, Belley-Cote E, Greco M, Laundy M,
Morgan JS, Kesecioglu J, McGeer A, Mermel L, Mammen MJ, Alexander PE, Arrington A, Centofanti J, Citerio G, Baw B,
Memish ZA, Hammond N, Hayden FG, Evans L, Rhodes A.
30GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
29
30
©2020 Baxter Healthcare Corporation
16
Clinical Nutrition, https://doi.org/10.1016/j.clnu.2020.03.022
ESPEN Expert Statements and Practical Guidance for Nutritional Management of Individuals with SARS-CoV-2 Infection
Barazzoni R, Bischoff SC, Krznaric Z, Pirlich M, Singer P,
endorsed by the ESPEN Council
31GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
Merker M, et al. JAMA Netw Open. 2020;3(3):e200663. doi:10.1001/jamanetworkopen.2020.0663
Association of Baseline Inflammation with Effectiveness of Nutritional Support Among Patients with Disease-related MalnutritionA Secondary Analysis of a Randomized Clinical Trial
Figure 2. Kaplan-Meier Estimate for Time to Death Within 30 Days According to Inflammatory Status
A) 30-Day Mortality in Overall Population
C) 30-Day Mortality Among Patients with Moderate Inflammation
D) 30-Day Mortality Among Patients with High Inflammation
B) 30-Day Mortality Among Patients with Low Inflammation
32GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
31
32
©2020 Baxter Healthcare Corporation
17
CORONAVIRUS DISEASE 2019
Unmet Needs and Unanswered Questions
33GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
Early Nutritional Supplementation in Non-critically Ill Patients Hospitalized for the 2019 Novel Coronavirus
Disease (COVID-19): Rationale and Feasibility of a Shared Pragmatic Protocol
Riccardo CaccialanzaUOC Dietetica e Nutrizione Clinica
Fondazione IRCCS Policlinico
San Matteo
r.caccialanza@smatteo.pv.it
34GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
33
34
©2020 Baxter Healthcare Corporation
18
35GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
• Changes in intestinal barrier
• Reduction in glomerular filtration
• Alterations in cardiac function
• Altered drug pharmacokinetics
• Delayed wound healing
• Increased surgical complications
• Increased treatment toxicity
• Impaired immunity
• Increase in length of hospital stay
• Increased hospital readmissions
• Increased mortality
• Increased treatment costs
• Impaired quality of life and functional status
Malnutrition/Cachexia: Consequences
Butterworth CE Jr. Nutrition Today 1974;9:4–8.
36GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
35
36
©2020 Baxter Healthcare Corporation
19
37GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
38GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
37
38
©2020 Baxter Healthcare Corporation
20
It is based on the observation that most patients present at admission with severe inflammation and anorexia leading
to the drastic reduction of food intake, and that a substantial percentage develops respiratory failure requiring
non-invasive ventilation or even continuous positive airway pressure.
Early Nutritional Supplementation in Non-critically Ill Patients Hospitalized for the 2019 Novel
Coronavirus Disease (COVID-19): Rationale and Feasibility of a Shared Pragmatic Protocol
Riccardo Caccialanza, M.D.; Alessandro Laviano, M.D, Ph.D.; Federica Lobascio, M.D; Elisabetta Montagna RD; Raffaele Bruno, M.D.; Serena Ludovisi, M.D.;
Angelo Guido Corsico, M.D., Ph.D.; Antonio Di Sabatino, M.D.; Mirko Belliato, M.D.; Monica Calvi Pharm.D.; Isabella Iacona, Pharm.D.; Giuseppina Grugnetti, R.N.;
Elisa Bonadeo, M.D.; Alba Muzzi, M.D.; Emanuele Cereda, M.D., Ph.D.
We are aware that our straight approach may be debatable. However, in order to cope with the current emergency
crisis, its aim is to promptly and pragmatically implement nutritional care in COVID-19 patients, which would risk to be
overlooked in spite of being potentially beneficial to clinical outcomes and effective in preventing the consequences
of malnutrition in this patient population.
39GLBL/MG17/20-0016(1) 04/2020 ©2020 Baxter Healthcare Corporation
Simplified nutritional risk screening§ Yes No
1 Is BMI <22 kg/m2?
2 Did the patient loose weight in the last 3 months?
3 Did the patient reduce food intake or is expected to reduce it in the next few days?
§If any answer is «Yes», start supplementation (between or straight after meals) with high-protein, high-calorie oral nutritional supplements (ONS; 2-3 bottles [125/200 ml each] providing 600-900 kcal and 35-55 grams of proteins).
*Use referred or estimated values if scales are not available or cannot be used due to hygienical reasons.
**Albumin, transferrin, prealbumin, glucose, kidney (creatinine and blood urea nitrogen) and liver (cholinesterase, aspartate amino-transferase, alanine amino-transferase, gamma glutamyl transferase) function, electrolytes (Na, K, Cl, Ca, P, Mg), triglyceride, folic acid, vitamina B12, 25-hydroxyvitamin D, C-reactive protein.
***Recommended dietary allowance.
Start Systematic Supplementation With:
• Whey proteins 20 g/day (in one or two occasions, preferably during meals)
• Daily infusion of RDA*** tailored multivitamin, multimineral and trace elements solutions (eg, in 100/250 mL of physiological saline solution)
• Cholecalciferol - 50.000 UI or 25.000 UI/week if 25-hydroxyvitamin D is <20 ng/mL or ≥20 <30 ng/mL, respectively.
If patients don’t tolerate ONS (ie, less than 2 bottles/day are consumed for 2 consecutive days) or respiratory conditions worsen, contact the Clinical Nutrition and Dietetics Unit for the prescription of parenteral nutrition or start it implementing strict biochemical monitoring**
DURING THE HOSPITAL STAY
Monitor food/supplements intake with the aid of local healthcare professionals.
Protocol for Early Nutritional Supplementation in Non-critically Ill COVID-19 Patients AT ADMISSION
Record:
• Body weight and height*
• Relevant biochemical parameters**
40GLBL/MG17/20-0016(1) 04/2020 ©2020 Baxter Healthcare Corporation
39
40
©2020 Baxter Healthcare Corporation
21
Cholecalciferol
50.000 UI/week if 25-OH vitamin D <20 ng/mL
25.000 UI/week if 25-OH vitamin D ≥20 <30 ng/mL
McPherson RA, et al. Curr Opin Clin Nutr Metab Care. 2011;14:562‐568; Rondanelli M, et al. Nutrition. 2020;72:110667; Teixeira FJ, et al. PharmacolRes. 2019;144:245-256; Cereda E, et al. Cancer Med. 2019; 8:6923-6932; Cross ML, et al. British J Nutr. 2000;84:S81‐S89; Ng TB, et al. Appl Microbiol Biotechnol. 2015;99:6997-7008; Olsen MF, et al. BMJ. 2014;348:g3187.
Systematic supplementation with:
Whey proteins 20 g/day (in one or two occasions, preferably
during meals)
• Anabolic and antioxidant properties + high digestibility
• Potential clinical benefits in cancer cachexia
• Immunomodulatory properties
• Potential antiviral activity
• Improved immune recovery in patients with HIV during ART
Daily e.v. infusion of RDA tailored multivitamin,
multimineral and trace elements solutions (eg, in 100/250 mL of
physiological saline solution)
• Anti-oxidant properties
• Specific vitamin and micronutrient deficits harmful during viral infections
• Approach is not precise (not available single nutrient dosage)
• May be beneficial with very limited risk of harm secondary to overdosing
Liu M, et al. Microbes Infect. 2017; 19:580-586; Beck MA. J Am Coll Nutr. 2001;20:384S-388S; Camini FC, et al. Arch Virol. 2017;162:907-917; Weger-Lucarelli J, et al. PLoS Pathog. 2019;15:e1008089; Evans P, et al. Br J Nutr. 2001;85:S67-74; Gupta S, et al. Cells. 2019;8(6); Beck MA. Nutr Rev. 1998;56:S140-6; Meyer M, et al. Am J Physiol Lung Cell Mol Physiol. 2015;308:L1189-201; Li Z, et al. Arch Virol. 2017;162:603-610; Baum MK, et al. JAMA. 2013;310:2154-63; Levett-Jones T. J Assoc Nurses AIDS Care. 2017;28:984-986; Tasca KI, et al. Oxid Med Cell Longev. 2017;2017:9834803; Isanaka S, et al. JAMA. 2012;308:1535-44; McGill JL, et al. Sci Rep. 2019;9:15157; Lee H, et al. Sci Rep. 2016;6:25835.
• Restoration to normal values in infected patients may improve immunologic recovery, reduce levels of inflammation and increase immunity against pathogens
Beard JA, et al. J Clin Virol. 2011;50:194-200; Teymoori-Rad M, et al. Rev Med Virol. 2019;29:e2032; Jiménez-Sousa MÁ, et al. Front Immunol. 2018;9:458; Havers F, et al. J Infect Dis. 2014;210:244-53; Gruber-Bzura BM. Int J Mol Sci. 2018;19. pii:E2419.
At Admission
41GLBL/MG17/20-0016(1) 04/2020 ©2020 Baxter Healthcare Corporation
§Referred or estimated weight & height values if scales are not available or cannot be used due to hygienical reasons.
*Albumin, transferrin, prealbumin, glucose, kidney (creatinine and blood urea nitrogen) and liver (cholinesterase, aspartate amino-transferase, alanine amino-transferase, gamma glutamyl transferase) function, electrolytes (Na, K, Cl, Ca, P, Mg), triglyceride, folic acid, vitamina B12, 25-hydroxyvitamin D, C-reactive protein.
Norman K, et al. Clin Nutr. 2008;27:5-15; Schuetz P, et al. Lancet. 2019;393:2312-2321; Gomes F, et al. Clin Nutr. 2018;37:336-353.
If any answer is «Yes»:
Start supplementation (between or straight after meals) with high-protein, high-calorie ONS (2-3 bottles [125/200 ml each] → 600-900 kcal /35-55 g proteins)
Relevant biochemical parameters collected*
At Admission
Simplified nutritional risk screening§ Yes No
1 Is BMI§ <22 kg/m2?
2 Did the patient loose weight in the last 3 months?
3 Did the patient reduce food intake or is expected to reduce it in the next few days?
42GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
41
42
©2020 Baxter Healthcare Corporation
22
Monitor food/ONS intake with the aid of local healthcare professional (as available…)
If patients don’t tolerate ONS (ie, less than 2 bottles/day are consumed for 2 consecutive days) or respiratory conditions worsen, contact the Clinical Nutrition and Dietetics Unit for the prescription
of parenteral nutrition or start it implementing strict biochemical monitoring
• NGT may result in air leakage and compromise the effectiveness of NIV or CPAP
• Special NIV masks with a port for NGT may be hardly available
• Positive pressure ventilation through a face mask may also result in gastric distention, further compromising the respiratory conditions
• Receiving EN during NIV was associated with a significantly higher rate of airway complications and longer NIV duration
• There is currently no validated strategy to reduce the critical complications of EN among patients with NIV or CPAP
• Patients receiving ART, frequently diarrhea that can contribute to treatment interruption
• Gastrointestinal symptoms are frequently reported by COVID-19, which may increase the risk of EN intolerance
Singer P, et al. Crit Care. 2018;22:27; Kogo M, et al. Respir Care. 2017;62:459-467; Kogo M, et al. Respir Care. 2017;62:1119-1120; Doig GS, et al. JAMA. 2013;309:2130-2138; Dikman AE, et al. Dig Dis Sci. 2015;60:2236-2245; Bezabih YM, et al. BMC Infect Dis. 2019;19:537; Pan L, et al. Am J Gastroenterol. 2020 [Epub ahead of print].
During the Hospital Stay
Why not enteral nutrition
43GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
Results: One hundred eighteen patients (90.1%) completed the 7-day SPN support regimen and 102 of them (86.4%) were in advanced disease stage. SPN induced a significant improvement of phase angle (PhA, + 0.25 [95% CI 0.11, 0.39]; p=0.001), standardized phase angle (SPA, + 0.33 [95% CI 0.13, 0.53]; p=0.002), HG (+ 2.1 kg -95% CI 1.30, 2.81]; p<0.001), and PAB (+ 3.8 mg/dL [95% CI 2.1, 5.6]; p<0.001). In multivariable analysis, the effects on BIVA parameters were more pronounced in patients (N=90, 76.3%) in whom estimated protein and calorie requirements were both satisfied (adjusted difference: PhA, + 0.39 [95% CI 0.04, 0.73]; p=0.030; SPA, + 0.62 [95% CI 0.16, 1.09]; p=0.009).
No significant changes in hydration status were detected and no severe metabolic or other complications occurred.
Conclusions: Early 7-day SPN resulted in improved body composition, HG and PAB levels in hypophagic, and hospitalized cancer patients at nutritional risk in the absence of any relevant clinical complications. Further trials, aimed at verifying the efficacy of this early nutritional intervention on mid- and long-term primary clinical endpoints in specific cancer types, are warranted.
Which Parenteral Nutrition (Ideally…)
Males
Females
44GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
43
44
©2020 Baxter Healthcare Corporation
23
• Limited accuracy of nutritional assessment and support due to weight and height measurement hard or even impossible to perform, like body composition assessment and calorimetry.
• Underfeeding very hard to avoid for several reasons: constantly increasing number of admitted patients; impossibility to assist patients during meals; monitoring of food intake extremely difficult, if feasible at all.
PN support may only partially fit the needs of pre-ICU COVID-19 patients due to:
• Central infusion lines not always available outside the ICU wards; elevated energy requirements (severe acute inflammatory response and average high patients’ BMI); cardiovascular and pulmonary compliance limit PN volume.
• Clinical Nutrition Units not widespread in Italian hospitals, thus specific competences in nutritional care not always available.
• Potentially problematic timely provision and availability of ONS, EN formulas, PN bags, infusion pumps.
Critical Issues and Perspectives
45GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
Specific nutritional support issues:
• COVID-19 disease can suddenly require intensive care measures, including intubation → EN
• EN tolerance (gastric distention, erosive gastritis)
• Supplemental PN
• Specific high protein-calorie, highly digestible enteral formulas enriched in anti-inflammatory or immunomodulatory nutrients
• Use of omega-3 fatty acids (anti-inflammatory/immunosuppressive properties)
• Clinical research focused on nutritional issues in COVID-19 patients is hard, if not impossible to perform.
Critical Issues and Perspectives (cont.)
46GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
45
46
©2020 Baxter Healthcare Corporation
24
However, any effort should be done to try to guarantee adequate nutritional support to hospitalized patients, as it may be potentially beneficial to clinical outcomes and effective in reducing or preventing the deleterious consequences of malnutrition in this patient population.
Conclusions
Implementing prompt and
appropriate nutritional care in
COVID-19 disease management
is a hard challenge due to the
current dramatic emergency
circumstances.
47GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
We are infinitively grateful to all the employees of the Fondazione IRCCS Policlinico San Matteo for their tremendous
and courageous efforts in struggling against the current tragic clinical and social COVID-19 emergency.
We are extremely grateful to all friends, medical nutrition industries and colleagues who will contribute to spread and share the challenge of implementing nutritional care in COVID-19 disease management.
Acknowledgments
48GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
47
48
©2020 Baxter Healthcare Corporation
25
QUESTIONS49GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
Baxter is a trademark of Baxter International Inc.
Thank you to all of those leading the fight against
COVID-19
50GLBL/MG17/20-0016 04/2020 ©2020 Baxter Healthcare Corporation
49
50
©2020 Baxter Healthcare Corporation
26
PLEASE REGISTER TODAY:https://www.baxterglobal.com/nutrition_hero_series
PART 4: ADDRESSING NUTRITIONAL CHALLENGES OF COVID-19 PATIENTS FROM ASSESSMENT TO DISCHARGE
Paul WischmeyerMD, EDIC, FASPEN, FCCMProfessor of Anesthesiology and Surgery
Associate Vice Chair for Clinical Research, Dept. of Anesthesiology
Physician Director, TPN/Nutrition Support Service, DUH
Duke University School of Medicine
Durham, NC, USA
FEATURING SPEAKER:
Thursday, April 30, 2020
at 08:00 PST/11:00 EST/16:00 BST/17:00 CEST
OBJECTIVES
• Define the best available guidance for nutritional requirements in COVID-19 patients using predictive equations and indirect calorimetry
• Describe strategies for managing nutritional challenges in paralysis, vasopressor use, prone position, CRRT, and ECMO
• Understand the role of early parenteral nutrition and supplemental parenteral nutrition in ICU and non-ICU COVID-19 patients
• Briefly discuss role of probiotics and Vitamin D to reduce risk and progression of COVID-19 infection
51GLBL/MG17/20-0015 04/2020 ©2020 Baxter Healthcare Corporation
51
top related